

**dutasteride 0.5mg plus tamsulosin 0.4mg capsule
(Combodart®) (No: 628/10)**

GlaxoSmithKline

Product Update

09 July 2010

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

dutasteride plus tamsulosin (Combodart®) is accepted for use within NHS Scotland.

Indications under review: Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH); Reduction in the risk of acute urinary retention and surgery in patients with moderate to severe-symptoms of BPH.

In patients for whom concomitant use of these medicines is appropriate, this combination allows administration of a single capsule at reduced cost compared to the individual components.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 12 May 2010.

**Chairman,
Scottish Medicines Consortium**